Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature.

ABSTRACT: Precision medicine offers remarkable potential for the treatment of cancer, but is largely focused on tumors that harbor actionable mutations. Gene expression signatures can expand the scope of precision medicine by predicting response to traditional (cytotoxic) chemotherapy agents without relying on changes in mutational status. We present a new signature extraction method, inspired by the principle of convergent phenotypes, which states that tumors with disparate genetic backgrounds may evolve similar phenotypes independently. This evolutionary-informed method can be utilized to produce consensus signatures predictive of response to over 200 chemotherapeutic drugs found in the Genomics of Drug Sensitivity in Cancer (GDSC) Database. Here, we demonstrate its use by extracting the Cisplatin

SUBMITTER: Scarborough JA 

PROVIDER: S-EPMC10115855 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature